Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study

ConclusionSimilar to the results of prospective and non-interventional studies, the low rates of symptomatic thromboembolic events and major bleeding in patients with atrial fibrillation undergoing ablation or cardioversion and treated with rivaroxaban in XANTUS suggest that its use is associated with an acceptable benefit –risk profile in this setting.Trial registration numberClinicaltrials.gov: NCT01606995.
Source: Europace - Category: Cardiology Source Type: research